unlocking the future of physics today
Nusano’s breakthrough technologies are creating radioisotope solutions for healthcare, industry and modern life
Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services. Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries.
Nusano
co-founders
HOWARD C. LEWIN, MD, FACC, FASNC
CO-FOUNDER & CHIEF PRODUCT DEVELOPMENT OFFICER
Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine. Read more >>
GLENN B. ROSENTHAL, PH.D.
CO-FOUNDER & CHIEF TECHNOLOGY OFFICER
Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer.
Read more >>
Nusano
Board of Directors
Scott Holbrook
NUSANO BOARD CHAIR & Chief Commercial and Manufacturing Officer, Ratio Therapeutics
Scott has over twenty years’ experience in the field of molecular imaging and therapeutics.
DELL LOY HANSEN
FOUNDER & CEO, WASATCH GROUP
Dell Loy Hansen is the Founder and Chief Executive Officer of the Wasatch Group and is responsible for the overall management of its enterprises and affiliates.
JOHN DAHLSTROM
EVP - GENERAL COUNSEL, WASATCH PROPERTY MANAGEMENT
John is General Counsel of Wasatch Property Management, a fully integrated real estate development, construction, property management and guaranty capital company operating in six states.
Aaron Gerszewski
Managing Director, Wasatch Equity Partners
Aaron is managing partner at Wasatch Equity Partners, an investment firm with more than $4 billion assets under management.
Andy Harrison
CEO, Section 32
Andy is Managing Director and CEO of Section 32, a venture capital fund investing at the frontiers of technology.
Michael Pellini
Managing Partner, Section 32
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology.
additional directors
company managers
Nusano’s CEO and CPDO, also serve on the Board of Directors.
Nusano
Advisors
Medical Isotope Advisory Board
Nusano’s Medical Isotope Advisory Board is a panel of internationally recognized leaders in nuclear medicine. The Board provides provide strategic guidance to Nusano, ensuring its medical radioisotope product development aligns with emerging trends and the needs of cancer patients. Read more >>
Strategic Advisory Board
The Strategic Advisory Board provides insights and guidance supporting the company’s commercialization of breakthrough radioisotope production and mass separation technologies for rapidly evolving industrial and commercial markets, including HALEU nuclear fuel production. Read more >>
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates